US$ 29.02
dihexa clinical trial human Dihexa
Description
Daly, L
This multi-receptor approach distinguishes it from existing licensed medicines such as semaglutide (Ozempic, Wegovy) or tirzepatide licensed in the UK as Mounjaro for type 2 diabetes and as Zepbound for obesity which act on fewer receptor pathways

Front Neurosci 2019;13:38

NaBPC157 maintained its salutary activity even after an extremely prolonged period of 48 hours
